Publications by authors named "Sarah Oelsner"

Claim this Profile
G
Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Sarah Oelsner, Anja Waldmann, Arne Billmeier, Jasmin Röder, Aline Lindner

Int J Cancer· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children.
Michael Merker, Verena Pfirrmann, Sarah Oelsner, Simone Fulda, Thomas Klingebiel

Oncotarget· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity.
Congcong Zhang, Pranav Oberoi, Sarah Oelsner, Anja Waldmann, Aline Lindner

Front Immunol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Sarah Oelsner, Miriam E Friede, Congcong Zhang, Juliane Wagner, Susanne Badura

Cytotherapy· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Sarah Oelsner, Juliane Wagner, Miriam E Friede, Verena Pfirrmann, Sabrina Genßler

Int J Cancer· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.
Sabrina Genßler, Michael C Burger, Congcong Zhang, Sarah Oelsner, Iris Mildenberger

Oncoimmunology· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
Verena Pfirrmann, Sarah Oelsner, Eva Rettinger, Sabine Huenecke, Halvard Bonig

Cytotherapy· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SMAC Mimetic BV6 Enables Sensitization of Resistant Tumor Cells but also Affects Cytokine-Induced Killer (CIK) Cells: A Potential Challenge for Combination Therapy.
Eva Rettinger, Andreas Glatthaar, Behnaz Ahangarian Abhari, Sarah Oelsner, Verena Pfirrmann

Front Pediatr· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis